PharmaEssentia (藥華藥) continues to see rapid growth driven by its flagship product, Ropeginterferon alfa-2b (Ropeg/Besremi), which is now a first-line treatment for Polycythemia Vera (PV) globally.

Regulatory and Pipeline Updates:

• US FDA Filings: A supplemental Biologics License Application (sBLA) for a pen injector has been submitted, with a PDUFA date of February 14, 2026.
• ET Indication: An application for Essential Thrombocythemia (ET) was submitted to the FDA in October 2025. Following an Applicant Orientation Meeting (AOM) in December, the case entered substantive review on December 29, 2025.
• HOPE-PMF Trial: A Phase III trial for early-prefibrotic or low-to-intermediate risk Primary Myelofibrosis (PMF) is underway, with patient enrollment expected to conclude in Q1 2026.
• Global Expansion: The company has signed a commercial licensing agreement with FORUS Therapeutics for the Canadian market and is initiating big-data-driven commercial analysis for payer communication in the US.

Resource: 藥華藥營運動能擴張，Ropeg多項申請推進成長